Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s breast cancer treatment approved in Scotland

February 9, 2021
Manufacturing and Production Takeda, breast cancer

The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …

News

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …

News
takeda_usa_pharmaceuticals_u

China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12

December 8, 2020
Manufacturing and Production, Sales and Marketing China, Takeda

China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …

News

Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy

November 30, 2020
Sales and Marketing Cabometyx, Japan, Takeda

The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …

News
takeda_usa_pharmaceuticals_u

Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan

October 29, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Japan, Moderna, Takeda, Vaccine

Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of …

News
shutterstock_273326141

Takeda and Arrowhead Pharma join forces in $1m rare liver disease drug development pact

October 9, 2020
Medical Communications, Research and Development Arrowhead, Takeda, pharma

A new partnership has been struck between Takeda and Arrowhead Pharmaceuticals, with both companies coming together to co-develop and license …

News
shutterstock_512649

Takeda to sell another non-core portfolio for $260 million to Cheplapharm

September 8, 2020
Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …

News

Takeda poised to cut sales jobs in Japan as restructuring continues

July 29, 2020
Medical Communications, Research and Development, Sales and Marketing Japan, Takeda, job cuts

Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …

News

NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma

July 9, 2020
Sales and Marketing Adcentris, NICE, Takeda, UK

NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …

News
shutterstock_138095450

Takeda jettisons non-core portfolio in Asia Pacific to Celltrion for a potential $278 million

June 12, 2020
Medical Communications, Sales and Marketing Takeda, celltrion, pharma, sale

Takeda continues its mission to reduce its debt in the wake of its $49 billion acquisition of Shire in January …

News
fda

FDA approves Takeda’s first-line treatment option for non-small cell lung cancer

May 26, 2020
Manufacturing and Production FDA, Takeda, approval

The FDA has approved Takeda’s Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

News
takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer

April 7, 2020
Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma

The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …

News

China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease

March 24, 2020
Manufacturing and Production Crohn's, Takeda, Takeda China

China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis …

News
takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

March 11, 2020
Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025